Paradigm Biopharmaceuticals Limited..
PAR.ASXHealth Care
Paradigm Biopharmaceuticals is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, dege
Market Data
$0.143
-0.0%$83.6M
-100000.0x
$-0.086
0.00%
-0.5%
Latest Earnings
Appendix 4D and Half Year Report
27 February 2026
Paradigm Biopharmaceuticals, a late-stage clinical development company, reported a loss of A$23.2M for H1 2025 (vs A$5.9M loss in H1 2024), reflecting accelerated investment in Phase 3 iPPS trial execution for knee osteoarthritis. The company is funded through mid-2026 and targeting an interim analysis of its pivotal PARA_OA_012 trial at Day 112 (mid-calendar 2026), a key de-risking milestone that management expects could catalyse regulatory, commercial and partnering discussions. Key points: Phase 3 PARA_OA_012 trial actively recruiting with 466 patients enrolled; 11 Australian sites and 48 US sites in advanced activation stages; Peer-reviewed publication of PARA_OA_008 Phase 2 biomarker data published in February 2026, providing independent validation of biological activity and clinically meaningful MRI structural findings; Secured US$27M convertible note facility; company is funded through interim analysis milestone with flexibility and reduced financing risk
Recent Announcements
Ceasing to be a substantial holder
Unable to provide a summary - the announcement text appears to be corrupted or encrypted (showing only repeated reversed text 'roF lanosrep esu ylno'). The content is unreadable and does not contain substantive information about who ceased being a substantial holder or relevant shareholding details.
Appendix 4D and Half Year Report
Paradigm Biopharmaceuticals, a late-stage clinical development company, reported a loss of A$23.2M for H1 2025 (vs A$5.9M loss in H1 2024), reflecting accelerated investment in Phase 3 iPPS trial execution for knee osteoarthritis. The company is funded through mid-2026 and targeting an interim analysis of its pivotal PARA_OA_012 trial at Day 112 (mid-calendar 2026), a key de-risking milestone that management expects could catalyse regulatory, commercial and partnering discussions. Key points: Phase 3 PARA_OA_012 trial actively recruiting with 466 patients enrolled; 11 Australian sites and 48 US sites in advanced activation stages; Peer-reviewed publication of PARA_OA_008 Phase 2 biomarker data published in February 2026, providing independent validation of biological activity and clinically meaningful MRI structural findings; Secured US$27M convertible note facility; company is funded through interim analysis milestone with flexibility and reduced financing risk
Get real-time alerts for PAR
Receive AI-powered earnings summaries and instant notifications when Paradigm Biopharmaceuticals Limited.. releases results.
Register Free